Radioligand therapy represents a transformative leap in precision medicine, combining the specific targeting capabilities of molecular ligands with the destructive power of radioactive isotopes. Unlike traditional external beam radiation, RLT works as a "search-and-destroy" mission within the body. A targeting molecule is engineered to seek out specific receptors overexpressed on cancer cells; once it binds to the target, it delivers a precise dose of radiation that kills the tumor while sparing surrounding healthy tissue. This "theranostic" approach—where the same ligand can be used for both imaging and treatment—is redefining how oncologists approach late-stage malignancies.

The US Radioligand Therapy (RLT) Market is experiencing a period of rapid clinical integration as providers move toward more personalized cancer care. The United States serves as a primary hub for this innovation, supported by a robust infrastructure of specialized nuclear medicine centers. Currently, the market is characterized by a high volume of treatments for prostate cancer and neuroendocrine tumors. By utilizing alpha and beta-emitting isotopes, clinicians are able to treat metastatic disease that was previously considered untreatable, offering a new pillar of therapy alongside surgery, chemotherapy, and immunotherapy.